首页> 外文期刊>Endocrine journal >Improvement of lymph node recurrence rate, but not distant recurrence and carcinoma death rates, in patients with papillary thyroid carcinoma after disease-free survival for 5 years
【24h】

Improvement of lymph node recurrence rate, but not distant recurrence and carcinoma death rates, in patients with papillary thyroid carcinoma after disease-free survival for 5 years

机译:甲状腺乳头状癌无病生存5年后,淋巴结复发率提高,但远处复发率和癌死率却没有改善

获取原文
获取原文并翻译 | 示例
           

摘要

In this study, we investigated the difference in lymph node-recurrence free survival (LN-RFS), distant recurrence-free survival (DRFS), and cause-specific survival (CSS) between patients with papillary thyroid carcinoma (PTC) in the entire group (Group I) and those with lymph node- and distant-recurrence-free survival (DFS) for 5 years after initial surgery (Group II). The LN-RFS of patients with all risk classifications in Group II was significantly better than that of those in Group I. The LN-RFS of intermediate-risk patients in Group II did not differ from that of low-risk patients in Group I, but LN-RFS of high-risk patients in Group II was significantly poorer than intermediate- and low-risk patients in Group I. DRFS and CSS of Group II patients did not significantly differ from those of Group I patients in the same risk classification. DRFS and CSS of high-risk patients in Group II were significantly poorer than those of intermediate- and low-risk patients in Group I, and those of intermediate-risk patients in Group II were also significantly poorer than those of low-risk patients in Group I. Taken together, the lymph node recurrence rate, but not distant recurrence and carcinoma death rates, of patients in all classifications significantly improved after DFS for 5 years. However, careful follow-up for lymph node recurrence of high-risk patients and for distant recurrence of intermediate- and high-risk patients is necessary thereafter.
机译:在这项研究中,我们调查了整个甲状腺乳头状癌(PTC)患者之间的淋巴结无复发生存率(LN-RFS),远距无复发生存率(DRFS)和原因特异性生存率(CSS)的差异组(I组)和初次手术后5年无淋巴结转移和无远处复发的患者(II组)。第二组中所有风险分类的患者的LN-RFS明显优于第一组。第二组中风险患者的LN-RFS与第一组低风险患者的LN-RFS并无差异,但是第二组的高危患者的LN-RFS显着低于第一组的中危和低危患者。在相同的风险分类中,第二组的DRFS和CSS与第一组的患者无显着差异。 II组高危患者的DRFS和CSS显着低于I组中中低危患者的DRFS和CSS,II组中中危患者的DRFS和CSS也显着低于I组中低危患者的DRFS和CSS I组。总的来说,DFS治疗5年后,所有分类的患者的淋巴结复发率均显着改善,但远处复发率和癌死率却没有明显改善。但是,此后有必要对高危患者的淋巴结复发以及中高危患者的远处复发进行认真的随访。

著录项

  • 来源
    《Endocrine journal》 |2012年第10期|p.895-901|共7页
  • 作者单位

    Department of Surgery, Kuma Hospital, Kobe 650-0011 Japan,Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, Kobe 650-0011, Japan;

    Department of Internal Medicine, Kuma Hospital, Kobe 650-0011 Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011 Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011 Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011 Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011 Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011 Japan;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    papillary carcinoma; thyroid; recurrence; survival;

    机译:乳头状癌甲状腺;复发生存;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号